PATENT Customer No. 24024 Attorney Docket No. 18525/04051

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)
Brooks and Peterson	) Group Art Unit: 1653
Application No.: 10/735,594	) Examiner: Marsha M. Tsay
Filed: December 13, 2003	) Attorney Docket No.: 18525/04051
For: Antagonists for Human Prolactin	)
Mail Stop Amendment	
Commissioner For Patents	
P.O. Box 1450	
Alexandria, VA 22313-1450	

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 CFR §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO/SB/08B. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of a Final Action, Quayle Action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or 02/17/2005 EAREGAY1 00000015 10735594

01 FC:1806

180.00 OF

Application/Patent No. 10/735,594

Attorney Docket No. 18525/04051

Supplemental Information Disclosure Statement

constitute "prior art." If the Examiner applies any of the documents as prior art against any

claim in the application and Applicants determine that the cited documents do not constitute

"prior art" under United States law, Applicants reserve the right to present to the office the

relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability

of the disclosed invention over the listed documents, should one or more of the documents be

applied against the claims of the present application.

If there is any fee due in connection with the filing of the Statement, please charge the fee

to our deposit account number 03-0172.

Respectfully submitted,

Date: February 4, 2005

Sean C. Myers-Payne

Reg. No. 42,920

Phone: (614) 621-7754 Fax: (614) 621-0010

E-mail: smyers-payne@calfee.com

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCEOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Complete if known				
Application Number	10/735,594			
Filing Date	December 12, 2003			
First Named Inventor	Charles L. Brooks			
Art Unit	1753			
Examiner's Name	Marsha M. Tsay			
Attorney Docket Number	18525/04051			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		PETERSON and BROOKS, "Different elements of mini-helix I are required for human growth hormone or prolactin action via the prolactin receptor", Protein Engineering, Design & Selection (2004) Volume 17, Number 5, Pages 417-424.	
		SIVAPRASAD <i>et al.</i> , "Mechanism for Ordered Receptor Binding by Human Prolactin", Biochemistry (2004) Volume 43, Pages 13755-13765.	
	,		

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.